CARM hosts first Open Innovation Investment Conference

Over 160 attendees, including 40 CARM members and over 30 investment organizations. 

CARM (Association for Advanced Regenerative Medicine, Chairman Kang Kyung-sun), a leading organization in Korea's advanced regenerative medicine industry, held its first Open Innovation Investment Conference.

The investment conference, held at COEX on the 23rd, was attended by a total of 160 people, including 40 CARM member companies and 30 specialized investment institutions.

The event attracted a lot of attention as the bio industry is facing various challenges, and Korea Investment Partners and Daily Partners, which are leading bio investors, served as sponsors.

The event began with a congratulatory speech from CARM Chairman Kang Kyung-sun, followed by encouraging remarks from Kim Young-hak, Director of the Ministry of Health and Welfare, Kim Young-man, Director of the Ministry of Trade, Industry and Energy, Kim Ki-kyung, Managing Director of the Korea Exchange, and Hwang Man-soon, CEO of Korea Investment Partners.

In his opening remarks, Chairman Kang Kyung-sun said, "Although the bio industry is currently experiencing difficulties, there is no doubt that the CGT (Cell & Gene Therapy) industry is the food of the future," and emphasized that "all industry participants should work together with a long-term perspective."

"We are very pleased that the event was successfully organized with great interest and encouragement from many people amidst the difficulties of the bio industry both internally and externally," said Lee Yi-il, Chairman of the Corporate Exchange Committee (CEO of Xcell Therapeutics), who was in charge of planning and executing the event. "We will grow this event into a representative investment conference in Korea with the belief that the bio industry is the last food of Korea."

A total of 14 CARM member companies, including Ipsel, Exostemtech, and Cellbio, participated in the IR presentation, followed by a lively Q&A session. The presenting companies' investment status ranged from Series A to C, attracting high interest from most investors who stayed until the end.

Source : Hit News (http://www.hitnews.co.kr)